Business
Lexaria Announces 2021 Annual Meeting Results
KELOWNA, BC / ACCESSWIRE / June 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in
About this update from Lexaria Bioscience Corp.
[{"type":"text","content":"KELOWNA, BC / ACCESSWIRE / June 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the \"Company\" or \"Lexaria\"), a global innovator in drug delivery platforms announces the results of the 2021 Annual Meeting (the 'Meeting').On June 28, 2021 at 1:00 p.m. (Pacific Time), the Company held the Meeting whereby there were 2,735,413 shares of the Company represented in person or by proxy at the meeting, constituting 53.6% of the Company's issued share capital as at May 3, 2021, being the record date of the Meeting. The matters voted upon at the Meeting and the final voting results are set forth below:Matter Being Voted OnForAgainstAbstainBroker Non-VotePercent Approved By1To Elect Chris Bunka as a director1,389,14430,9387,7031,307,62897.2%To Elect John Docherty as a director1,175,573245,3946,8181,307,62882.3%To Elect Nicholas Baxter as a director1,171,626249,2766,8831,307,62882.1%To Elect Ted McKechnie as a director1,394,63526,3106,8401,307,62897.7%To Elect Albert Reese Jr. as a director1,393,76527,1676,8531,307,62897.6%To Appoint Davidson & Company LLP as Auditors2,713,11417,7924,504099.2%To Approve an amendment to the Company's Equity Incentive Plan for the issuance of an additional 249,143 common shares975,355442,8169,6141,307,62868.3%To ratify the lawful actions of the directors for the past year1,225,53155,303146,9511,307,62885.8%1 Percentage is calculated based on abstained votes being counted as a vote against the resolutionAll of the proposals are described in detail in the Company's proxy statement filed with the Securities Exchange Commission via Edgar and with the BC Securities Commission and Ontario Securities Commission via SEDAR on May 14, 2021.About Lexaria Bioscience Corp.Lexaria Bioscience Corp.'s proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company's technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH has repeatedly demonstrated since 2016 with cannabinoids and nicotine the ability to increase bio-absorption by up to 5-10x, reduce time of onset from 1 - 2 hours ...